VTI investment case, page-8

the best facts I can establish on the topic are:

1) of the projected potential market place US is $2bn of the global potential $20bn

2) the only equivalent daily disposable product is the Coopervision MiSight which is inferior in terms of the addressable caseload and range of population

3) eye care professionals in the U.S. currently use VTI “Natural View for treating myopia progression as it employs a unique optical design that has been shown in peer reviewed, published data to slow the progression of myopia in children by over 90%.iMiSight is available in distance powers up to -6.00 diopters. NVMF is available in a full range of distance powers, up to -12.25 diopters, enabling treatment of a greater portion of the myopic population than MiSight.Visioneering Technologies CEO Ste” from VTI asx release 20/11/19

4) Coopervision results comments from CEO below on their MiSight which they only introduced to the US this year shows they expect $25m revenue next year and for that to double the year after. He also comments he believes it’s a ‘multi billion, dollar opportunity’